325
Participants
Start Date
August 15, 2017
Primary Completion Date
December 31, 2024
Study Completion Date
June 30, 2025
AL3818
Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
Dacarbazine
Dacarbazine 1000 mg/m2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle
AL3818 or placebo
AL3818 or placebo 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
University of Pittsburgh Medical Center, Pittsburgh
Thomas Jefferson Hospital - Sidney Kimmel Cancer Center, Philadelphia
Mayo Clinic Jacksonville, Jacksonville
University of Miami Sylvester Comprehensive Cancer Center, Miami
Vanderbilt University, Nashville
University of Michigan Comprehensive Cancer Center, Ann Arbor
Mayo Clinic Rochester, Rochester
Northwestern University, Chicago
Washington University St. Louis, St Louis
MD Anderson Cancer Center, Houston
University of Colorado Denver, Aurora
Mayo Clinic Arizona, Phoenix
Sarcoma Oncology Center, Santa Monica
University of California Los Angeles, Los Angeles
Stanford Medicine Cancer Institute, Stanford
UW Medicine-Seattle Cancer Care Alliance, Seattle
Beijing Cancer Hospital, Beijing
Shanghai Sixth People's Hospital, Shanghai
Istituto Nazionale dei Tumori, Milan
University of Palermo, Palermo
University Campus Bio-Medico, Rome
Hospital de la Santa Creu i Sant Pau, Barcelona
Royal Marsden Hospital, London
Lead Sponsor
Advenchen Laboratories, LLC
INDUSTRY